| Literature DB >> 28239495 |
Michele Vitacca1, Laura Comini2, Marilena Barbisoni2, Gloria Francolini2, Mara Paneroni1, Jean Pierre Ramponi2.
Abstract
This retrospective study aimed to evaluate, through an ad hoc 17-item tool, the Pulmonary Rehabilitation Decisional Score (PRDS), the priority access to PR prescription by respiratory specialists. The PRDS, scoring functional, clinical, disability, frailty, and participation parameters from 0 = low priority to 34 = very high priority for PR access, was retrospectively calculated on 124 specialist reports sent to the GP of subjects (aged 71 ± 11 years, FEV1% 51 ± 17) consecutively admitted to our respiratory outpatient clinic. From the specialist's report the final subject's allocation could be low priority (LP) (>60 days), high priority (HP) (30-60 days), or very high priority (VHP) (<30 days) to rehabilitation. The PRDS calculation showed scores significantly higher in VHP versus LP (p < 0.001) and significantly different between HP and VHP (p < 0.001). Comparing the specialist's allocation decision and priority choice based on PRDS cut-offs, PR prescription was significantly more appropriate in VHP than in HP (p = 0.016). Specialists underprescribed PR in 49% of LP cases and overprescribed it in 46% and 30% of the HP and VHP prescriptions, respectively. A multicomprehensive score is feasible being useful for staging the clinical priorities for PR prescription and facilitating sustainability of the health system.Entities:
Year: 2017 PMID: 28239495 PMCID: PMC5292400 DOI: 10.1155/2017/5710676
Source DB: PubMed Journal: Rehabil Res Pract ISSN: 2090-2867
Pulmonary Rehabilitation Decisional Score (PRDS).
| ITEMS | Score | ||
|---|---|---|---|
| 0 | 1 | 2 | |
| Age, years | ≤59 | 60–74 | ≥75 |
| BMI, Kg/m2 | 21–24 | 25–30 | ≤20 or ≥31 |
| FEV1% pred. | ≥65% | 36–64% | ≤35% |
| Dyspnea, MRC score (0–4) | 0-1 | =2 | ≥3 |
| 6MWT, meters | ≥350 | ≤349 and ≥250 | ≤249 |
| CAT score | ≤9 | 10–15 | ≥16 |
| Comorbidities | 0 | 1 | 1 if cardiac/neurological or >1 |
| Activity of daily life | Normal | Limited | Bedridden/wheelchair-restricted |
| Severe exacerbations in the last year | 0 | 1 | >1 |
| Hospitalizations in the last year | 0 | 0, but 1 ER access | >0 or 2 ER access instances |
| Smoking status | Nonsmoker | Ex-smoker | Current smoker |
| Physical activity (cyclette, walking, steps) | >4 h/week | 2–4 h/week | <2 h/week |
| Subjective wellbeing | Very well/good | Poor | bad |
| Depression | No medications | Occasional medications | Under chronic therapy |
| Anxiety | No medications | Occasional medications | Under chronic therapy |
| Care need and availability | Not necessary | Useful and available full time | Useful but available on spot or unavailable |
| Adherence to medications/oxygen | Full | Not constant | Poor/refusal to comply |
FEV1 = forced expiratory volume at first second; MRC = Medical Research Council; ER = emergency room; W = week; BMI = body mass index; CAT = COPD Assessment Tool; 6MWT = 6-min walking test. Consensus was considered when more than 75% of the respondents (a) rated each item as mandatory to be inserted in the score when considered “important” and/or “very important” and (b) agreed to each item's grading from 0 = minimum to 2 = maximum priority indication for PR. Exacerbation was defined as “an event requiring antibiotics and/or oral steroids as prescribed by specialist or patient's GP.”
Demographic, anthropometric, and functional characteristics of study patients.
| Whole | LP | HP | VHP |
| |
|---|---|---|---|---|---|
| Patients, | 124 | 41 | 37 | 46 | |
| Age, years | 71 ± 11 | 72 ± 12 | 68 ± 11& | 74 ± 8 | 0.031 |
| Males, | 73 | 25 | 18 | 30 | ns |
| BMI, Kg/m2 | 24 ± 3 | 23 ± 2 | 25 ± 3$ | 24 ± 4 | 0.0120 |
| Smokers, | 24 | 8 | 7 | 9 | ns |
| Ex-smokers, | 61 | 15 | 19 | 27 | ns |
| SatO2, % | 94 ± 2 | 95 ± 2 | 94 ± 2° | 93 ± 2 | <0.0001 |
| FEV1, % pred. | 51 ± 17 | 57 ± 15 | 55 ± 16? | 43 ± 17 | 0.0002 |
| FVC, % pred. | 78 ± 23 | 86 ± 19 | 85 ± 19° | 66 ± 23 | <0.0001 |
| FEV1/FVC% | 65 ± 7 | 65 ± 6 | 64 ± 9 | 65 ± 6 | ns |
| CAT, score | 14 ± 6 | 10 ± 4 | 14 ± 5∧,& | 17 ± 6 | <0.0001 |
| 6MWT, meters | 321 ± 131 | 382 ± 144 | 369 ± 115° | 228 ± 62 | <0.0001 |
LP = low priority; HP = high priority; VHP = very high priority. BMI = body mass index; SatO2 = pulsed arterial saturation; FEV1 = forced expiratory volume at first second; FVC = forced vital capacity; CAT = COPD Assessment Tool; 6MWT = 6-min walking test. $p < 0.05, ∧p < 0.01, and p < 0.001 versus LP; &p < 0.05, ?p < 0.01, and °p < 0.001 versus VHP.
Figure 1PRDS score, calculated on single report at the time of outpatients visit. Median value indicates the score to be given to the specialist's prescription for low priority (LP, circles, n = 41); high priority (HP, triangles, n = 37); and very high priority (VHP, squares, n = 46). Dotted lines at 11 and 18 delimit the arbitrary cut-offs of PR priority, that is, for LP (0–10), HP (11–17), and VHP (18–34). One-way ANOVA was performed to compare differences among settings and, where significant, Bonferroni's multiple comparison was applied as post hoc test. A p value < 0.05 was considered statistically significant.
Figure 2Percentage of adequate prescription (white bars), underprescription (row bars), and overprescription (black bars) of PR rehabilitation in the LP, HP, and VHP groups according to the PRDS cut-off values proposed (LP: 0–10, HP: 11–17, and VHP: 18–34). A test of proportion (test Zeta) was performed to compare differences in the percentage of appropriate prescription, underprescription, and overprescription of PR as decided by the specialist at the outpatient visit. A p value < 0.05 was considered statistically significant.